Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.

Nature medicine - 1 Aug 2002

Hoshijima Masahiko, Ikeda Yasuhiro, Iwanaga Yoshitaka, Minamisawa Susumu, Date Moto-o, Gu Yusu, Iwatate Mitsuo, Li Manxiang, Wang Lili, Wilson James M, Wang Yibin, Ross John, Chien Kenneth R

Abstract excerpt

The feasibility of gene therapy for cardiomyopathy, heart failure and other chronic cardiac muscle diseases is so far unproven. Here, we developed an in vivo recombinant adeno-associated virus (rAAV) transcoronary delivery system that allows stable, high efficiency and relatively cardiac-selective gene expression. We used rAAV to express a pseudophosphorylated mutant of human phospholamban (PLN), a key regulator...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aorta
Share to Calcium-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dependovirus

Share to Gene Transfer Techniques

Share to Genetic Therapy

Share to Hemodynamics

Share to Myocardium

Share to Sarcoplasmic Reticulum

Source

Identifiers

PMID: 12134142
DOI: 10.1038/nm739

Genes

PLN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.PMID 12134142Read ↗

Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.Semantic proximity Read ↗

Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function.Semantic proximity Read ↗

A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.Semantic proximity Read ↗

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and humanSemantic proximity Read ↗

Phospholamban as a crucial determinant of the inotropic response of human pluripotent stem cell-derived ventricular cardiomyocytes and engineered 3-dimensional tissue constructs.Semantic proximity Read ↗

Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failureSemantic proximity Read ↗

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathySemantic proximity Read ↗

Sarcoplasmic reticulum Ca<sup>2+</sup>ATPase as a therapeutic target for heart failureSemantic proximity Read ↗

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.Semantic proximity Read ↗

Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.Semantic proximity Read ↗

Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.Semantic proximity Read ↗

Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transferSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.